Genmab AS (GMAB) reports a 19% revenue increase and a 56% rise in operating profit, showcasing strong financial performance ...

Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst ...

Genmab ( ($GMAB) ) just unveiled an update. On August 13, 2025, Genmab A/S announced updates to its Articles of Association, including ...

Genmab's (GMAB) stock gains as its lymphoma drug epcoritamab developed with AbbVie (ABBV) succeeds in a Phase 3 lymphoma ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Shares of Genmab A/S Sponsored ADR (GMAB) have gained 3.8% over the past four weeks to close the last trading session at ...

Genmab (GMAB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Genmab A/S (NASDAQ:GMAB) is one of the Best Extremely Profitable Stocks to Buy Right Now. On July 16, Genmab A/S (NASDAQ:GMAB) announced new sales figures for DARZALEX as of the second quarter of ...

Danish biotech Genmab (Nasdaq: GMAB) posted second-quarter revenue of $925 million, up 19% from a year earlier, driven by ...

Danish biotech Genmab (Nasdaq: GMAB) and US partner AbbVie (NYSE: ABBV) have reported a decisive win in a Phase III study of ...

Genmab A/S (NASDAQ:GMAB – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Monday. Several other ...

Investing.com -- Shares of Genmab A/S (CSE: GMAB) rose after the Danish biotech company reported second-quarter earnings that beat expectations, driven by strong sales of Darzalex and positive trial ...